All Stories

  1. Renal adverse events in EGFR-TKI treatment: Comprehensive characterization of clinical patterns and molecular underpinnings

    Article • Genes & Diseases, July 2026, Tsinghua University Press

    Peng Luo

  2. Correspondence to “Which came first, the cannabis or the depression?”

    Article • Preventive Medicine Reports, June 2024, Elsevier

    Peng Luo

  3. PESSA: A web tool for pathway enrichment score-based survival analysis in cancer

    Article • PLoS Computational Biology, May 2024, PLOS

    Peng Luo

  4. The Evaluation of Generative AI Should Include Repetition to Assess Stability

    Article • JMIR mhealth and uhealth, May 2024, JMIR Publications Inc.

    Peng Luo

  5. Co-alteration of Myc and RTK-RAS pathways defines a liver-metastatic propensity and immune-cold subgroup of pancreatic adenocarcinoma

    Article • Genes & Diseases, May 2024, Tsinghua University Press

    Peng Luo

  6. CD209 signaling pathway as a biomarker for cisplatin chemotherapy response in small cell lung cancer

    Article • Genes & Diseases, May 2024, Tsinghua University Press

    Peng Luo

  7. ChatGPT’s ability to generate realistic experimental images poses a new challenge to academic integrity

    Article • Journal of Hematology & Oncology, May 2024, Springer Science + Business Media

    Peng Luo

  8. Large-scale genome-wide association studies reveal the genetic causal etiology between air pollutants and autoimmune diseases

    Article • Journal of Translational Medicine, April 2024, Springer Science + Business Media

    Peng Luo

  9. MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level

    Article • Cancer Biology & Therapy, April 2024, Taylor & Francis

    Peng Luo

  10. Development and validation of a radiosensitivity model to evaluate radiotherapy benefits in pan‐cancer

    Article • Cancer Science, April 2024, Wiley

    Peng Luo

  11. Potential of Large Language Models as Tools Against Medical Disinformation

    Article • JAMA Internal Medicine, April 2024, American Medical Association (AMA)

    Peng Luo

  12. SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma

    Article • Clinical Genitourinary Cancer, April 2024, Elsevier

    Peng Luo

  13. MOCS, a novel classifier system integrated multimoics analysis refining molecular subtypes and prognosis for skin melanoma

    Article • Journal of Biomolecular Structure and Dynamics, March 2024, Taylor & Francis

    Peng Luo

  14. Language and cultural bias in AI: comparing the performance of large language models developed in different countries on Traditional Chinese Medicine highlights the need for localized models

    Article • Journal of Translational Medicine, March 2024, Springer Science + Business Media

    Peng Luo

  15. Role of body mass index and weight change in the risk of cancer: A systematic review and meta-analysis of 66 cohort studies

    Article • Journal of Global Health, March 2024, Edinburgh University Global Health Society

    Peng Luo

  16. CTLs heterogeneity and plasticity: implications for cancer immunotherapy

    Article • Molecular Cancer, March 2024, Springer Science + Business Media

    Peng Luo

  17. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review

    Article • Journal of Translational Medicine, March 2024, Springer Science + Business Media

    Peng Luo

  18. OralExplorer: a web server for exploring the mechanisms of oral inflammatory diseases

    Article • Journal of Translational Medicine, March 2024, Springer Science + Business Media

    Peng Luo

  19. PMI-controlled mannose metabolism and glycosylation determines tissue tolerance and virus fitness

    Article • Nature Communications, March 2024, Springer Science + Business Media

    Peng Luo

  20. The Evaluation of Generative AI Should Include Repetition to Assess Stability (Preprint)

    Article • March 2024, JMIR Publications Inc.

    Peng Luo

  21. Unlocking the potential of T‐cell metabolism reprogramming: Advancing single‐cell approaches for precision immunotherapy in tumour immunity

    Article • Clinical and Translational Medicine, March 2024, Wiley

    Peng Luo

  22. Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies

    Article • ESMO Open, March 2024, Elsevier

    Peng Luo

  23. Can DALL-E 3 Reliably Generate 12-Lead ECGs and Teaching Illustrations?

    Article • Cureus, January 2024, Springer Science + Business Media

    Peng Luo

  24. IOBR2: Multidimensional Decoding Tumor Microenvironment for Immuno-Oncology Research

    Article • January 2024, Cold Spring Harbor Laboratory Press

    Peng Luo

  25. TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy

    Article • Journal for ImmunoTherapy of Cancer, January 2024, BMJ

    Peng Luo

  26. Oxidative stress is involved in immunosuppression and macrophage regulation in glioblastoma

    Article • Clinical Immunology, January 2024, Elsevier

    Peng Luo

  27. The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma

    Article • Heliyon, January 2024, Elsevier

    Peng Luo

  28. Cellular Ligand–Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer

    Article • Journal of Proteome Research, December 2023, American Chemical Society (ACS)

    Peng Luo

  29. Correlation between IL3 signaling pathway-related genes and immune checkpoint inhibitor efficacy in patients with renal cell carcinoma

    Article • Cancer Biomarkers, December 2023, IOS Press

    Peng Luo

  30. Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients

    Article • BJS, December 2023, Oxford University Press (OUP)

    Peng Luo

  31. THER: Integrative Web Tool for Tumor Hypoxia Exploration and Research

    Article • November 2023, Cold Spring Harbor Laboratory Press

    Peng Luo

  32. Multimodal ChatGPT-4V for ECG Interpretation: Promise and Limitations (Preprint)

    Article • Journal of Medical Internet Research, November 2023, JMIR Publications Inc.

    Peng Luo

  33. The regulatory role and clinical application prospects of circRNA in the occurrence and development of CNS tumors

    Article • CNS Neuroscience & Therapeutics, November 2023, Wiley

    Peng Luo

  34. A tumor-infiltrating immune cells-related pseudogenes signature based on machine-learning predicts outcomes and immunotherapy responses in ovarian cancer

    Article • Cellular Signalling, November 2023, Elsevier

    Peng Luo

  35. BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors

    Article • Journal Of Big Data, November 2023, Springer Science + Business Media

    Peng Luo

  36. Oncogenic pathways refine a new perspective on the classification of hepatocellular carcinoma

    Article • Cellular Signalling, November 2023, Elsevier

    Peng Luo

  37. A TGF‐β signaling‐related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

    Article • CNS Neuroscience & Therapeutics, October 2023, Wiley

    Peng Luo

  38. PD-L1-related IncRNAs are associated with malignant characteristics and immune microenvironment in glioma

    Article • Aging, October 2023, Impact Journals, LLC

    Peng Luo

  39. The causal relationship between air pollution, obesity, and COVID-19 risk: a large-scale genetic correlation study

    Article • Frontiers in Endocrinology, October 2023, Frontiers

    Peng Luo

  40. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

    Article • Molecular Cancer, October 2023, Springer Science + Business Media

    Peng Luo

  41. Association of cannabis use with depression among cancer patients

    Article • Preventive Medicine Reports, October 2023, Elsevier

    Peng Luo

  42. Global burden of neoplasms attributable to specific occupational carcinogens over 30 years: a population-based study

    Article • Public Health, October 2023, Elsevier

    Peng Luo

  43. Immune perturbation network identifies an EMT subtype with chromosomal instability and tumor immune-desert microenvironment

    Article • iScience, October 2023, Elsevier

    Peng Luo

  44. TCCIA: A Comprehensive Resource for Exploring CircRNA in Cancer Immunotherapy

    Article • August 2023, Cold Spring Harbor Laboratory Press

    Peng Luo

  45. Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses

    Article • Journal Of Big Data, August 2023, Springer Science + Business Media

    Peng Luo

  46. CACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma

    Article • Immunotherapy, August 2023, Taylor & Francis

    Peng Luo

  47. Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis

    Article • Molecular Cancer, August 2023, Springer Science + Business Media

    Peng Luo

  48. HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus‐associated cancers

    Article • iMeta, August 2023, Wiley

    Peng Luo

  49. Mutations in the DNA polymerase binding pathway affect the immune microenvironment of patients with small‐cell lung cancer and enhance the efficacy of platinum‐based chemotherapy

    Article • Cancer Innovation, July 2023, Tsinghua University Press

    Peng Luo

  50. Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity

    Article • iScience, July 2023, Elsevier

    Peng Luo

  51. Profiles of immune infiltration in seasonal allergic rhinitis and related genes and pathways

    Article • International Immunopharmacology, July 2023, Elsevier

    Peng Luo

  52. Burden of cardiovascular disease among elderly: based on the Global Burden of Disease Study 2019

    Article • European Heart Journal - Quality of Care and Clinical Outcomes, June 2023, Oxford University Press (OUP)

    Peng Luo

  53. Identification of a single cell-based signature for predicting prognosis risk and immunotherapy response in patients with glioblastoma

    Article • Clinical Immunology, June 2023, Elsevier

    Peng Luo

  54. Immunosenescence: molecular mechanisms and diseases

    Article • Signal Transduction and Targeted Therapy, May 2023, Springer Science + Business Media

    Peng Luo

  55. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

    Article • EClinicalMedicine, May 2023, Elsevier

    Peng Luo

  56. Tumor-secreted lactate contributes to an immunosuppressive microenvironment and affects CD8 T-cell infiltration in glioblastoma

    Article • Frontiers in Immunology, April 2023, Frontiers

    Peng Luo

  57. Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma

    Article • Cell Death and Disease, April 2023, Springer Science + Business Media

    Peng Luo

  58. Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer

    Article • Journal of Inflammation Research, April 2023, Taylor & Francis

    Peng Luo

  59. Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”

    Article • International Journal of Cancer, March 2023, Wiley

    Peng Luo

  60. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma

    Article • World Journal of Surgical Oncology, March 2023, Springer Science + Business Media

    Peng Luo

  61. An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms

    Article • Cell Proliferation, February 2023, Wiley

    Peng Luo

  62. Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment

    Article • Molecular Cancer, February 2023, Springer Science + Business Media

    Peng Luo

  63. Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma

    Article • Oxidative Medicine and Cellular Longevity, February 2023, Hindawi Publishing Corporation

    Peng Luo

  64. Comprehensive analysis of pyroptosis‐related gene signatures for glioblastoma immune microenvironment and target therapy

    Article • Cell Proliferation, January 2023, Wiley

    Peng Luo

  65. Editorial: Combining chemo/radio therapy and immunotherapy for cancers—perfect mix of old and new

    Article • Frontiers in Immunology, January 2023, Frontiers

    Peng Luo

  66. RNA modification pattern‐based subtypes reveal heterogenous clinical outcomes and tumor immunity of clear cell renal cell carcinoma

    Article • MedComm – Future Medicine, January 2023, Wiley

    Peng Luo

  67. A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma

    Article • Cell & Bioscience, December 2022, Springer Science + Business Media

    Peng Luo

  68. PanCanSurvPlot: A Large-scale Pan-cancer Survival Analysis Web Application

    Article • December 2022, Cold Spring Harbor Laboratory Press

    Peng Luo

  69. A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy

    Article • Frontiers in Immunology, December 2022, Frontiers

    Peng Luo

  70. Activation of the TGF-β Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients

    Article • Disease Markers, December 2022, Hindawi Publishing Corporation

    Peng Luo

  71. Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma

    Article • Frontiers in Immunology, December 2022, Frontiers

    Peng Luo

  72. Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy

    Article • Cancer Gene Therapy, December 2022, Springer Science + Business Media

    Peng Luo

  73. Molecular insight into pentraxin-3: Update advances in innate immunity, inflammation, tissue remodeling, diseases, and drug role

    Article • Biomedicine & Pharmacotherapy, December 2022, Elsevier

    Peng Luo

  74. Machine learning-based identification of SOX10 as an immune regulator of macrophage in gliomas

    Article • Frontiers in Immunology, November 2022, Frontiers

    Peng Luo

  75. A novel thinking: DDR axis refines the classification of ccRCC with distinctive prognosis, multi omics landscape and management strategy

    Article • Frontiers in Public Health, November 2022, Frontiers

    Peng Luo

  76. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis

    Article • International Journal of Cancer, November 2022, Wiley

    Peng Luo

  77. HOXA5: A crucial transcriptional factor in cancer and a potential therapeutic target

    Article • Biomedicine & Pharmacotherapy, November 2022, Elsevier

    Peng Luo

  78. Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets

    Article • Frontiers in Immunology, October 2022, Frontiers

    Peng Luo

  79. BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors

    Article • October 2022, Cold Spring Harbor Laboratory Press

    Peng Luo

  80. Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

    Article • Molecular Cancer, October 2022, Springer Science + Business Media

    Peng Luo

  81. Hyaluronic acids mediate the infiltration, migration, and M2 polarization of macrophages: evaluating metabolic molecular phenotypes in gliomas

    Article • Molecular Oncology, October 2022, Wiley

    Peng Luo

  82. Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM

    Article • Frontiers in Immunology, September 2022, Frontiers

    Peng Luo

  83. Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma

    Article • Briefings in Bioinformatics, September 2022, Oxford University Press (OUP)

    Peng Luo

  84. MOAHIT: a web tool for visualizing tumor multi-omics data with human anatomy heatmaps

    Article • September 2022, Cold Spring Harbor Laboratory Press

    Peng Luo

  85. Large-scale bulk RNA-seq analysis defines immune evasion mechanism related to mast cell in gliomas

    Article • Frontiers in Immunology, September 2022, Frontiers

    Peng Luo

  86. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

    Article • Journal of Experimental & Clinical Cancer Research, September 2022, Springer Science + Business Media

    Peng Luo

  87. B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis

    Article • Journal of Inflammation Research, September 2022, Taylor & Francis

    Peng Luo

  88. Pericyte mediates the infiltration, migration, and polarization of macrophages by CD163/MCAM axis in glioblastoma

    Article • iScience, September 2022, Elsevier

    Peng Luo

  89. Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management

    Article • Medical Oncology, August 2022, Springer Science + Business Media

    Peng Luo

  90. Identification of a Hypoxia-Angiogenesis lncRNA Signature Participating in Immunosuppression in Gastric Cancer

    Article • Journal of Immunology Research, August 2022, Hindawi Publishing Corporation

    Peng Luo

  91. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

    Article • Journal of Hematology & Oncology, August 2022, Springer Science + Business Media

    Peng Luo

  92. Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy

    Article • Frontiers in Immunology, August 2022, Frontiers

    Peng Luo

  93. Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study

    Article • Cancer Innovation, August 2022, Wiley

    Peng Luo

  94. A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis

    Article • Frontiers in Immunology, August 2022, Frontiers

    Peng Luo

  95. A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma

    Article • Frontiers in Immunology, July 2022, Frontiers

    Peng Luo

  96. Relationship between ATOH1 and tumor microenvironment in colon adenocarcinoma patients with different microsatellite instability status

    Article • Cancer Cell International, July 2022, Springer Science + Business Media

    Peng Luo

  97. A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma

    Article • Journal of Oncology, July 2022, Hindawi Publishing Corporation

    Peng Luo

  98. JMJD8 Is an M2 Macrophage Biomarker, and It Associates With DNA Damage Repair to Facilitate Stemness Maintenance, Chemoresistance, and Immunosuppression in Pan-Cancer

    Article • Frontiers in Immunology, July 2022, Frontiers

    Peng Luo

  99. Application of ATAC-seq in tumor-specific T cell exhaustion

    Article • Cancer Gene Therapy, July 2022, Springer Science + Business Media

    Peng Luo

  100. ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer

    Article • Frontiers in Immunology, June 2022, Frontiers

    Peng Luo

  101. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment

    Article • Journal of Immunology Research, June 2022, Hindawi Publishing Corporation

    Peng Luo

  102. Corrigendum: Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response

    Article • Frontiers in Immunology, June 2022, Frontiers

    Peng Luo

  103. Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report

    Article • JTO Clinical and Research Reports, June 2022, Elsevier

    Peng Luo

  104. THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients

    Article • Drug Design Development and Therapy, June 2022, Taylor & Francis

    Peng Luo

  105. NRBF2 regulates the chemoresistance of small cell lung cancer by interacting with the P62 protein in the autophagy process

    Article • iScience, June 2022, Elsevier

    Peng Luo

  106. Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma

    Article • Cancer Cell International, May 2022, Springer Science + Business Media

    Peng Luo

  107. Prognostic Factors and Treatment Strategies for Elderly Patients with Malignant Meningioma: A SEER Population-Based Study

    Article • Frontiers in Oncology, May 2022, Frontiers

    Peng Luo

  108. Deep Learning Analysis of the Adipose Tissue and the Prediction of Prognosis in Colorectal Cancer

    Article • Frontiers in Nutrition, May 2022, Frontiers

    Peng Luo

  109. UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer

    Article • Bioengineered, May 2022, Taylor & Francis

    Peng Luo

  110. Cell plasticity in patients with NSCLC: The controversial origins of transformed SCLC

    Article • Biomedicine & Pharmacotherapy, May 2022, Elsevier

    Peng Luo

  111. Genomic and immunological profiles of small-cell lung cancer between East Asians and Caucasian

    Article • Cancer Cell International, April 2022, Springer Science + Business Media

    Peng Luo

  112. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma

    Article • Frontiers in Immunology, April 2022, Frontiers

    Peng Luo

  113. Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis

    Article • Frontiers in Cell and Developmental Biology, April 2022, Frontiers

    Peng Luo

  114. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer

    Article • Briefings in Bioinformatics, April 2022, Oxford University Press (OUP)

    Peng Luo

  115. Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer

    Article • Frontiers in Immunology, April 2022, Frontiers

    Peng Luo

  116. Targeting papain-like protease for broad-spectrum coronavirus inhibition

    Article • Protein & Cell, April 2022, Oxford University Press (OUP)

    Peng Luo

  117. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals

    Article • Cellular and Molecular Immunology, March 2022, Springer Science + Business Media

    Peng Luo

  118. Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response

    Article • Frontiers in Immunology, March 2022, Frontiers

    Peng Luo

  119. MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer

    Article • Frontiers in Cell and Developmental Biology, February 2022, Frontiers

    Peng Luo

  120. Deep learning analysis of the adipose tissue and the prediction of prognosis in colorectal cancer.

    Article • Journal of Clinical Oncology, February 2022, American Society of Clinical Oncology (ASCO)

    Peng Luo

  121. Survival Analysis of TP53 Comutations Should Be Interpreted More Cautiously

    Article • Journal of Thoracic Oncology, February 2022, Elsevier

    Peng Luo

  122. CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

    Article • Frontiers in Cell and Developmental Biology, January 2022, Frontiers

    Peng Luo

  123. A Systematic Review of Neurologic Toxicity and Psychiatric Adverse Events associated with Immune Checkpoint Inhibitors

    Article • PanCancer, January 2022, International Biomed Press

    Peng Luo

  124. Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma

    Article • Theranostics, January 2022, Ivyspring International Publisher

    Peng Luo

  125. Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma

    Article • Frontiers in Cell and Developmental Biology, November 2021, Frontiers

    Peng Luo

  126. Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes

    Article • Frontiers in Immunology, November 2021, Frontiers

    Peng Luo

  127. Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma

    Article • Frontiers in Pharmacology, October 2021, Frontiers

    Peng Luo

  128. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

    Article • Frontiers in Cell and Developmental Biology, September 2021, Frontiers

    Peng Luo

  129. High mutations in fatty acid metabolism contribute to a better prognosis of small‐cell lung cancer patients treated with chemotherapy

    Article • Cancer Medicine, September 2021, Wiley

    Peng Luo

  130. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

    Article • Frontiers in Immunology, September 2021, Frontiers

    Peng Luo

  131. Applications of Machine Learning to Predict Cisplatin Resistance in Lung Cancer

    Article • International Journal of General Medicine, September 2021, Taylor & Francis

    Peng Luo

  132. Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer

    Article • Annals of Translational Medicine, September 2021, AME Publishing Company

    Peng Luo

  133. Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma

    Article • Frontiers in Pharmacology, August 2021, Frontiers

    Peng Luo

  134. Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration

    Article • Frontiers in Oncology, June 2021, Frontiers

    Peng Luo

  135. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma

    Article • Frontiers in Immunology, June 2021, Frontiers

    Peng Luo

  136. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors

    Article • Frontiers in Pharmacology, June 2021, Frontiers

    Peng Luo

  137. Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma

    Article • Frontiers in Molecular Biosciences, May 2021, Frontiers

    Peng Luo

  138. Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer

    Article • Frontiers in Immunology, March 2021, Frontiers

    Peng Luo

  139. Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma

    Article • Cancer Biomarkers, February 2021, IOS Press

    Peng Luo

  140. Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets

    Article • Computational and Structural Biotechnology Journal, January 2021, Elsevier

    Peng Luo

  141. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer

    Article • Frontiers in Cell and Developmental Biology, December 2020, Frontiers

    Peng Luo

  142. Emerging Concern of Scientific Fraud: Deep Learning and Image Manipulation

    Article • November 2020, Cold Spring Harbor Laboratory Press

    Peng Luo

  143. A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis

    Article • Cancer Cell International, November 2020, Springer Science + Business Media

    Peng Luo

  144. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma

    Article • Biomedicine & Pharmacotherapy, November 2020, Elsevier

    Peng Luo

  145. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer

    Article • Pharmacological Research, September 2020, Elsevier

    Peng Luo

  146. ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment

    Article • Frontiers in Genetics, August 2020, Frontiers

    Peng Luo

  147. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer

    Article • Frontiers in Immunology, August 2020, Frontiers

    Peng Luo

  148. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors

    Article • Frontiers in Pharmacology, August 2020, Frontiers

    Peng Luo

  149. EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma

    Article • Cancer Gene Therapy, August 2020, Springer Science + Business Media

    Peng Luo

  150. Current status, challenges and perspectives: immunotherapy and tumour microenvironment in thoracic cancer

    Article • Journal of Thoracic Disease, August 2020, AME Publishing Company

    Peng Luo

  151. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer

    Article • Medical Oncology, July 2020, Springer Science + Business Media

    Peng Luo

  152. DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer

    Article • Aging, January 2020, Impact Journals, LLC

    Peng Luo

  153. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

    Article • Cancer Control, January 2020, SAGE Publications

    Peng Luo

  154. Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis

    Article • Journal of Cancer, January 2020, Ivyspring International Publisher

    Peng Luo

  155. DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing

    Article • Journal of Thoracic Oncology, December 2019, Elsevier

    Peng Luo

  156. Association between Circulating Inflammatory Proteins and Clinical Prognosis in Chinese Patients with EGFR Mutation–Positive Non–Small Cell Lung Cancer

    Article • Journal of Thoracic Oncology, October 2019, Elsevier

    Peng Luo

  157. Immune Cell Infiltration Is a Strong Prognostic Indicator in Surgical Resection of SCLC

    Article • Journal of Thoracic Oncology, October 2019, Elsevier

    Peng Luo

  158. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

    Article • Molecular Cancer, September 2019, Springer Science + Business Media

    Peng Luo

  159. Comparison of the incidence of colorectal cancer in young adults between the USA and Europe

    Article • Gut, July 2019, BMJ

    Peng Luo

  160. Author's Reply to: Osimertinib and jaw osteonecrosis? A case report

    Article • International Journal of Cancer, June 2019, Wiley

    Peng Luo

  161. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer

    Article • Drug Design Development and Therapy, June 2019, Dove Medical Press

    Peng Luo, Lin Weiyin

  162. Cervical cancer harboring a Rb1 mutation may sensitize to cisplatin via PI3K/AKT pathway by regulating apoptosis.

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Peng Luo

  163. Identification of aberrantly methylated differentially expressed genes in breast cancer by integrated bioinformatics analysis

    Article • Journal of Cellular Biochemistry, May 2019, Wiley

    Peng Luo

  164. The efficacy of the new medical internship management network system

    Article • Medicine, February 2019, Wolters Kluwer Health

    Peng Luo

  165. Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis

    Article • Expert Review of Gastroenterology & Hepatology, January 2019, Taylor & Francis

    Peng Luo

  166. Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis

    Article • International Journal of Cancer, January 2019, Wiley

    Peng Luo

  167. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter

    Article • Theranostics, January 2019, Ivyspring International Publisher

    Peng Luo

  168. The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis

    Article • Cancer Medicine, September 2018, Wiley

    Peng Luo

  169. Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap

    Article • Drug Design Development and Therapy, August 2018, Dove Medical Press

    Peng Luo, Xu xinjie

  170. Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer

    Article • Drug Design Development and Therapy, August 2018, Dove Medical Press

    Peng Luo

  171. Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis

    Article • Gynecologic Oncology, June 2018, Elsevier

    Peng Luo

  172. The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis

    Article • OncoTargets and Therapy, March 2018, Dove Medical Press

    Ruolan Qian, Peng Luo

  173. Glia maturation factor-β: a potential therapeutic target in neurodegeneration and neuroinflammation

    Article • February 2018, Dove Medical Press

    Peng Luo, Chuyun Chen

  174. Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis

    Article • Journal of Cancer, January 2018, Ivyspring International Publisher

    Peng Luo

  175. Three-dimensional visualization of the functional fascicular groups of a long-segment peripheral nerve

    Article • Neural Regeneration Research, January 2018, Medknow

    Peng Luo

  176. The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor

    Article • Cancer Management and Research, December 2017, Dove Medical Press

    Peng Luo

  177. The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer

    Article • Drug Design Development and Therapy, November 2017, Dove Medical Press

    Peng Luo, Ruolan Qian

  178. PUB025 Efficacy of ALK Inhibitors in the Treatment of ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases: A Meta-analysis

    Article • Journal of Thoracic Oncology, November 2017, Elsevier

    Peng Luo

  179. The relationship between neutrophil-to-lymphocyte ratio and diabetic peripheral neuropathy in Type 2 diabetes mellitus

    Article • Medicine, November 2017, Wolters Kluwer Health

    Peng Luo

  180. Continuous intrathecal administration of liposomal amphotericin B for treatment of refractory Cryptococcus neoformans encephalitis: A case report

    Article • Experimental and Therapeutic Medicine, June 2017, Spandidos Publications

    Peng Luo

  181. Kennedy disease with difficulty in differential diagnosis

    Article • Medicine, May 2017, Wolters Kluwer Health

    Peng Luo

  182. The Relationship between Neutrophil-to-Lymphocyte Ratio and Intracerebral Hemorrhage in Type 2 Diabetes Mellitus

    Article • Journal of Stroke and Cerebrovascular Diseases, May 2017, Elsevier

    Peng Luo

  183. Efficiency and safety of roflumilast combined with long-acting bronchodilators on moderate-to-severe stable chronic obstructive pulmonary disease patients: a meta-analysis

    Article • Journal of Thoracic Disease, September 2016, AME Publishing Company

    Peng Luo

  184. Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients

    Article • BMC Endocrine Disorders, March 2015, Springer Science + Business Media

    Peng Luo